248 related articles for article (PubMed ID: 6181870)
1. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
Vogelzang NJ; Lange PH; Goldman A; Vessela RH; Fraley EE; Kennedy BJ
Cancer Res; 1982 Nov; 42(11):4855-61. PubMed ID: 6181870
[TBL] [Abstract][Full Text] [Related]
2. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):129-34. PubMed ID: 6170953
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of disseminated seminoma.
Einhorn LH; Williams SD
Cancer Clin Trials; 1980; 3(4):307-13. PubMed ID: 6159120
[TBL] [Abstract][Full Text] [Related]
4. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
Toner GC; Geller NL; Tan C; Nisselbaum J; Bosl GJ
Cancer Res; 1990 Sep; 50(18):5904-10. PubMed ID: 1697503
[TBL] [Abstract][Full Text] [Related]
5. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
Suurmeijer AJ; Oosterhuis JW; Marrink J; De Bruin HW; Schraffordt Koops H; Sleijfer DT; Fleuren GJ
Oncodev Biol Med; 1983; 4(4):289-308. PubMed ID: 6188132
[TBL] [Abstract][Full Text] [Related]
6. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
[TBL] [Abstract][Full Text] [Related]
7. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
8. Advanced male non-seminomatous germ-cell tumours. Combination chemotherapy with cis-platinum, vinblastine and bleomycin.
Woods RL; Fox RM; Tattersall MH
Med J Aust; 1979 Dec; 2(12):630-2. PubMed ID: 94148
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
10. [Tumor marker diagnosis in non-seminomatous testicular tumors using human chorionic gonadotropin (HCG) and alpha fetoprotein (AFP)].
Boewer C; Nawka S; Fleck H; Uibel M; Immer U; Schmidt HE; Herzmann H; Pilgrim G; Ziegenbein R
Z Urol Nephrol; 1985 Feb; 78(2):77-86. PubMed ID: 2581393
[TBL] [Abstract][Full Text] [Related]
11. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
12. [A case of alpha-fetoprotein producing primary intracranial embryonal carcinoma treated with combination chemotherapy with cis-platinum, vinblastine and bleomycin (author's transl)].
Nakajima F; Pak S; Fujitsu K; Kuwabara T
No Shinkei Geka; 1981; 9(3):371-5. PubMed ID: 6165918
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
Keskin S; Ekenel M; Başaran M; Bavbek S
Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
[TBL] [Abstract][Full Text] [Related]
16. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
17. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
18. [Progress in the therapy of testicular teratoid tumors].
Seeber S
Wien Med Wochenschr; 1982 Jul; 132(13-14):329-33. PubMed ID: 6182701
[TBL] [Abstract][Full Text] [Related]
19. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
Christensen TB; Engbaek F; Marqversen J; Nielsen SI; Kamby C; von der Maase H
Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
[TBL] [Abstract][Full Text] [Related]
20. Reduced dose PVB treatment of stage IIC-IV testicular seminoma.
Berkmen F
Eur J Surg Oncol; 1993 Feb; 19(1):24-6. PubMed ID: 7679655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]